US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

AGEN

Agenus (AGEN)

Agenus Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AGEN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/24	23 : 00	Business Wire	Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting	NASDAQ:AGEN	Agenus Inc
2024/04/23	20 : 30	Business Wire	Agenus to Provide First Quarter 2024 Financial Report and Corporate Update	NASDAQ:AGEN	Agenus Inc
2024/04/12	20 : 30	Business Wire	Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	NASDAQ:AGEN	Agenus Inc
2024/04/06	05 : 30	Business Wire	Agenus Announces Reverse Stock Split of Common Stock	NASDAQ:AGEN	Agenus Inc
2024/03/14	20 : 30	Business Wire	Agenus Reports Fourth Quarter and Full Year 2023 Results	NASDAQ:AGEN	Agenus Inc
2024/03/06	21 : 30	Business Wire	Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024	NASDAQ:AGEN	Agenus Inc
2024/03/06	06 : 30	Business Wire	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:AGEN	Agenus Inc
2024/03/01	06 : 50	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AGEN	Agenus Inc
2024/02/29	21 : 30	Business Wire	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	NASDAQ:AGEN	Agenus Inc
2024/02/27	06 : 24	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:AGEN	Agenus Inc
2024/02/26	21 : 30	Business Wire	Agenus to Participate in Leerink Partners Global Biopharma Conference	NASDAQ:AGEN	Agenus Inc
2024/02/15	22 : 02	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:AGEN	Agenus Inc
2024/02/15	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AGEN	Agenus Inc
2024/02/15	21 : 02	PR Newswire (US)	Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design	NASDAQ:AGEN	Agenus Inc
2024/02/14	22 : 33	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:AGEN	Agenus Inc
2024/02/12	21 : 00	Edgar (US Regulatory)	Form 5 - Annual statement of changes in beneficial ownership of securities	NASDAQ:AGEN	Agenus Inc
2024/02/12	21 : 00	Edgar (US Regulatory)	Form 5 - Annual statement of changes in beneficial ownership of securities	NASDAQ:AGEN	Agenus Inc
2024/02/10	07 : 11	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:AGEN	Agenus Inc
2024/01/31	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AGEN	Agenus Inc
2024/01/31	21 : 30	Business Wire	Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:AGEN	Agenus Inc
2024/01/22	23 : 59	Business Wire	Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population	NASDAQ:AGEN	Agenus Inc
2024/01/22	21 : 30	Business Wire	Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population	NASDAQ:AGEN	Agenus Inc
2024/01/06	06 : 30	Business Wire	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:AGEN	Agenus Inc
2024/01/04	21 : 30	Business Wire	Agenus to Participate in B. Riley Healthcare Conference	NASDAQ:AGEN	Agenus Inc
2024/01/04	20 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGEN	Agenus Inc
2024/01/04	20 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGEN	Agenus Inc
2024/01/04	20 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AGEN	Agenus Inc
2023/12/20	21 : 30	Business Wire	Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024	NASDAQ:AGEN	Agenus Inc
2023/12/11	21 : 30	Business Wire	Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program	NASDAQ:AGEN	Agenus Inc
2023/12/09	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AGEN	Agenus Inc

Showing the most relevant articles for your search:NASDAQ:AGEN

1 2 3 4 5 6 7 8 9 10 次へ >>

US Dollar vs Yen

US Dollar vs Sterling

Invesco QQQ Trust Series 1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約